Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-tampering legislation

This article was originally published in The Tan Sheet

Executive Summary

HR 2100, which would make the destruction or alteration of product identification codes punishable by fines ranging from $500 to $1 mil., was the subject of an Oct. 21 House Judiciary/Intellectual Property Subcommittee hearing. Concerns raised at the hearing addressed potential consumer harm related to purchasing products of questionable merit. However, American Free Trade Association counsel Gilbert Sandler testifies the bill would place unwarranted restrictions on numerous companies. Similar legislation was introduced by sponsor Robert Goodlatte (R-Va.) in the last Congress, but the measure failed to receive the required two-thirds vote under a suspension of the rules, failing 245-167 (1"The Tan Sheet" Oct. 5, 1998, p. 27). The Consumer Healthcare Products Association is a strong advocate of the bill; companion legislation could be introduced in the Senate by Orrin Hatch (R-Utah) or Patrick Leahy (D-Vt.)

You may also be interested in...



Anticounterfeiting Bill Rejected On House Floor Sept. 28

The Trademark Anticounterfeiting Act legislation (HR 3891) was rejected on the House floor Sept. 28 under a suspension of rules by a voice vote of 245-167. Under the suspension of rules procedures, a two-thirds vote would have been needed to pass the measure.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel